<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02495064</url>
  </required_header>
  <id_info>
    <org_study_id>MianyangCH</org_study_id>
    <nct_id>NCT02495064</nct_id>
  </id_info>
  <brief_title>Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients</brief_title>
  <official_title>Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Receiving Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yao Liao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mianyang Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiation dermatitis is an acute effect of radiation therapy,Especially in the neck skin of
      head and neck squamous cell carcinomas' patients.The investigators wanted to confirm the
      benefit of mometasone furoate (MF) in preventing acute radiation reactions, as shown in a
      previous study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized,self-comparative controlled trial was undertaken comparing MF cream with no
      cream administered from the first day of treatment for 5-6 weeks to prevent radiation
      dermatitis of neck during radiation therapy to the head and neck squamous cell carcinomas'
      Patients.

      One side of patients' neck will begin to use MF cream from the first day of radiation
      therapy, while the other side accept no preventive measures.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the mean Radiation Therapy Oncology Group (RTOG) skin dermatitis score</measure>
    <time_frame>seven weeks</time_frame>
    <description>The investigators descriph the skin dermatitis scores every week during radiation therapy and the later two weeks as follows:The scores were 0 = no visible change; 1 = faint or dull erythema; 2 = tender or bright erythema with or without moist desquamation; 3 = patchy moist desquamation with moderate edema; and 4= confluent moist desquamation with pitting edema.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Early Radiation Dermatitis</condition>
  <arm_group>
    <arm_group_label>Mometasone Furoate Cream(MF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants will be given conventional Chemoradiotherapy and MF.
MF Brief introduction:
Generic name :Mometasone Furoate Cream. Dosage form:Each gram of Mometasone Furoate Cream contains mometasone furoate, USP in a cream base of hexylene glycol, phosphoric acid, propylene glycol stearate, stearyl alcohol and ceteareth-20, titanium dioxide, aluminum starch octenylsuccinate, white wax, white petrolatum, and purified water.
Dosage:Apply a thin film of Mometasone Furoate Cream to the affected skin areas once daily during radiotherapy.
It is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>conventional Chemoradiotherapy only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone Furoate Cream</intervention_name>
    <description>One side of patients' neck will begain to use MF cream from the first day of radiation therapy.</description>
    <arm_group_label>Mometasone Furoate Cream(MF)</arm_group_label>
    <other_name>Eloson</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathological diagnosis for head and neck squamous cell carcinomas and

          -  going to have radiotherapy.

        Exclusion Criteria:

          -  pregnant,

          -  lactating women,

          -  infants,

          -  elderly people with atrophy skin,

          -  allergic constitution patients,

          -  the corresponding parts of 5 radiotherapy skin ulceration or infection and

          -  allergic patients to Mometasone Furoate Cream.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang dong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health Bureau of Mian Yang</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liao Yao</last_name>
    <phone>0086-13778106466</phone>
    <email>425838503@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Du X Bo</last_name>
    <phone>0086-13550822229</phone>
    <email>duxiaobo2005@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>oncology department of Mian yang central Hosptial</name>
      <address>
        <city>Mianyang</city>
        <state>Sichuan</state>
        <zip>0816</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liao Yao, Resident</last_name>
      <phone>0086-13778106466</phone>
      <email>425838503@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Du x bo, Chief</last_name>
      <phone>0086-13550822229</phone>
      <email>duxiaobo2005@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2015</study_first_submitted>
  <study_first_submitted_qc>July 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2015</study_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mianyang Central Hospital</investigator_affiliation>
    <investigator_full_name>Yao Liao</investigator_full_name>
    <investigator_title>Doctor of oncology department in Mianyang Central Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

